Literature DB >> 25915454

The Efficacy and Safety of Tamsulosin Combined with Extracorporeal Shockwave Lithotripsy for Urolithiasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Kai Chen1, Hua Mi2, Guangyu Xu1, Lin Liu3, Xiubin Sun1, Shiping Wang1, Qingrong Meng1, Tao Lv1.   

Abstract

BACKGROUND AND
PURPOSE: Many studies have been conducted to investigate adjunctive tamsulosin therapy after extracorporeal shockwave lithotripsy (SWL) for urolithiasis. The results from those studies, however, are still inconsistent. Therefore, we performed a meta-analysis to provide an update on the clinical efficacy and safety of tamsulosin combined with SWL for urolithiasis.
METHODS: A systematic search was performed in PubMed, Cochrane Library, and Embase to identify all relevant randomized controlled trials until January 2015. Two reviewers independently assessed trial quality and extracted data. Meta-analysis was conducted with Review Manager (RevMan), version 5.1.
RESULTS: Twenty-one studies (2093 subjects in total) were identified in the current meta-analysis. Compared with a control group, the experimental group (tamsulosin combined with SWL) showed an increased overall benefit for stone expulsion, with pooled risk ratio (RR) of 1.20 (95% confidence interval [CI], 1.15-1.26). With respect to the different geographic regions, European and American had a high possibility of improvement in stone expulsion (RR: 1.33, 95% CI, 1.19-1.49). According to the stone locations (renal, upper and lower ureteral) and sizes (4-10 mm and 11-24 mm), tamsulosin is more useful for lower ureteral stone (RR: 1.28; 95% CI, 1.14-1.43) and larger sized stones (RR: 1.49; 95% CI, 1.28-1.75). The effect estimates did not vary markedly when stratified by follow-up durations but varied by dose of tamsulosin. Furthermore, a shorter expulsion time, reduced occurrence of steinstrasse, fewer incidences of colic, and lower analgesic requirements were observed within the experimental group. In addition, tamsulosin is well tolerated, and its adverse events rarely led to dropouts of patients.
CONCLUSIONS: Overall, evidence suggests that tamsulosin combined with SWL is safe and effective in enhancing stone expulsion for patients with urolithiasis. Furthermore, high-quality, randomized and placebo-controlled trials evaluating the efficacy and safety of tamsulosin should be performed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25915454     DOI: 10.1089/end.2015.0098

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  5 in total

1.  Canadian Urological Association guideline: Management of ureteral calculi - Abridged version.

Authors:  Jason Y Lee; Sero Andonian; Naeem Bhojani; Jennifer Bjazevic; Ben H Chew; Shubha De; Hazem Elmansy; Andrea G Lantz-Powers; Kenneth T Pace; Trevor D Schuler; Rajiv K Singal; Peter Wang; Michael Ordon
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

2.  Canadian Urological Association guideline: Management of ureteral calculi - Full-text.

Authors:  Jason Y Lee; Sero Andonian; Naeem Bhojani; Jennifer Bjazevic; Ben H Chew; Shubha De; Hazem Elmansy; Andrea G Lantz-Powers; Kenneth T Pace; Trevor D Schuler; Rajiv K Singal; Peter Wang; Michael Ordon
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

3.  The Influence of Pain on the Outcome of Extracorporeal Shockwave Lithotripsy.

Authors:  Elke Bovelander; Saskia Weltings; Mandana Rad; Paulien van Kampen; Rob C M Pelger; Hossain Roshani
Journal:  Curr Urol       Date:  2019-03-08

Review 4.  Adjunctive medical expulsive therapy with tamsulosin for repeated extracorporeal shock wave lithotripsy: a systematic review and meta-analysis.

Authors:  Wei Ouyang; Guoliang Sun; Gongwei Long; Man Liu; Hua Xu; Zhiqiang Chen; Zhangqun Ye; Heng Li; Yucong Zhang
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

Review 5.  Indications and contraindications for shock wave lithotripsy and how to improve outcomes.

Authors:  Luke F Reynolds; Tad Kroczak; Kenneth T Pace
Journal:  Asian J Urol       Date:  2018-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.